Rhythm Pharmaceuticals 株価情報 (NASDAQ: RYTM)

最新ニュース Rhythm Pharmaceuticals (NASDAQ:RYTM) 株価情報

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals Inc

<p><strong>Oppenheimer </strong>initiated coverage on <strong>Rhythm Pharmaceuticals Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a developer of treatment for rare obesity disorders.</p>
<p>The pharmaceutical industry&#8217;s focus on weight management is drawing strong investor interest, with Rhythm Pharmaceuticals standing out for targeting rare obesity disorders that standard treatments often fail to address.</p>
<p>The company is steadily growing its business through the global rollout of Imcivree, a drug designed for several<a href="https://www.benzinga.com/pressreleases/24/12/g42284805/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-receives-expanded-marketing-authorization-" target="_blank" rel="noreferrer noopener"> genetic obesity conditions</a>.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com//node/42613036">Novo Nordisk&#8217;s Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges</a></strong></p>
<p>Revenue from global sales of IMCIVREE was $33.3 million for the third quarter of 2024, an increase of 14% on a sequential basis, primarily driven by sales for BBS.</p>
<p>In the third quarter of 2024, revenue of $23.3 million, or 70% of product revenue, was <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41757397/rhythm-pharmaceuticals-reports-third-quarter-2024-financial-results-and-business-update" rel="noreferrer noopener">generated in the U.S.</a></p>
<p>Oppenheimer is optimistic about its progress in treating hypothalamic obesity, an acquired condition with high development potential, as Phase 3 trial results are expected in the first half of 2025.</p>
<p>Oppenheimer initiated coverage on Rhythm Pharmaceuticals with an Outperform rating and a <a target="_blank" href="https://www.benzinga.com/quote/RYTM/analyst-ratings" rel="noreferrer noopener">price target of $76</a>.</p>
<p>Rhythm&#8217;s expertise in MC4 biology positions it for long-term success as Imcivree&#8217;s approved uses expand, new pipeline drugs with improved efficacy and convenience advance, and the company enhances its efforts to identify patients with genetic obesity.</p>
<p>The analyst anticipates significant growth opportunities in 2025 and beyond as Rhythm taps into a multi-billion-dollar total addressable market.</p>
<p>The analyst highlights that severe obesity caused by MC4R pathway defects doesn&#8217;t respond well to popular GLP-1 drugs like <strong>Novo Nordisk A/S&#8217;</strong>&nbsp;&nbsp;Wegovy or <strong>Eli Lilly And Co&#8217;s</strong> Zepbound, noting the experts and studies.</p>
<p>The MC4R drug market has little competition. <strong>Palatin Technologies Inc. </strong>markets Vyleesi (bremelanotide) for sexual disorders and is testing it with Zepbound for general obesity, with results expected in early 2025. Palatin is also developing oral MC4R drugs.</p>
<p><strong>Price Action:</strong> RYTM stock is up 1.71% at $56.43 at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/12/42623020/why-innovative-industrial-stock-is-falling-over-20-today" target="_blank" rel="noreferrer noopener">Innovative Industrial Properties Hit By Cannabis Company PharmaCann&#8217;s Rent Default, Stock Plunges</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Analyst Color

Biotech

Equities

News

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

RYTM

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

<p>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration&nbsp;(FDA) has approved an expanded indication for IMCIVREE&#xAE; (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency.</p>
<p>BBS and POMC, PCSK1 and LEPR deficiencies are rare melanocortin-4 receptor (MC4R) pathway diseases with hallmark characteristics that include hyperphagia, or pathological, insatiable hunger and impaired satiety accompanied by persistent and abnormal food-seeking behaviors, and early-onset obesity. IMCIVREE is the first and only precision medicine to target impairment of the hypothalamic MC4R pathway, a root cause of hyperphagia and obesity due to BBS and POMC, PCSK1 and LEPR deficiencies in adults and children as young as 2 years old in the United States, as well as Europe.</p>


hythm Pharmaceuticals Secures FDA Approval For Expanded Use Of IMCIVREE To Treat Obesity In Children As Young As 2 With Bardet-Biedl Syndrome Or MC4R Pathway Deficiencies, Targeting Rare Neuroendocrine Diseases

<p>Ratings for Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $67.36, a high estimate of $80.00, and a low estimate of $52.00. This upward trend is evident, with the current average reflecting a 6.5% increase from the previous average price target of $63.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734696012_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Rhythm Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$76.00</td>
<td>-</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$69.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$69.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rhythm Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Rhythm Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Rhythm Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rhythm Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Get to Know Rhythm Pharmaceuticals Better</h2>
<p>Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.</p>
<h3>Unraveling the Financial Story of Rhythm Pharmaceuticals</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Rhythm Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>47.76%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Rhythm Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of <strong>-131.25%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Rhythm Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-172.64%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-11.71%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Rhythm Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>0.36</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals

<p>Oppenheimer  analyst Leland Gershell   initiates coverage on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Outperform rating and announces Price Target of $76.</p>


Oppenheimer Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating, Announces Price Target of $76

<p>Goldman Sachs  analyst Corinne Jenkins   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $59 to $66.</p>


Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $66

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $69 price target.</p>


Reiteration

HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $69 Price Target

<p>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom's Medicines &amp; Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE&#xAE;&nbsp;(setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) or genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or biallelic leptin receptor (LEPR) deficiency&nbsp;in adult and pediatric patients as young as 2 years old and older.</p>


Government

Regulations

Rhythm Pharma's IMCIVREE (Setmelanotide) Bags Expanded Marketing Authorization In The UK for Treatment Of Obesity And Control Of Hunger In Patients With Bardet Biedl Syndrome

<p>Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Rhythm Pharmaceuticals and provided 12-month price targets. The average target is $66.15, accompanied by a high estimate of $80.00 and a low estimate of $52.00. This upward trend is evident, with the current average reflecting a 4.83% increase from the previous average price target of $63.10.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732539688_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of Rhythm Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$69.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$64.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Rhythm Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Rhythm Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rhythm Pharmaceuticals analyst ratings.</strong></a></p>
<h2>About Rhythm Pharmaceuticals</h2>
<p>Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.</p>
<h3>Breaking Down Rhythm Pharmaceuticals's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Rhythm Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>47.76%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Rhythm Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-131.25%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-172.64%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-11.71%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.36</strong>, Rhythm Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts

<p>Canaccord Genuity  analyst Whitney Ijem   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $80 price target.</p>


Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Maintains $80 Price Target

<p>Rhythm enrolled 12 patients in its open-label 52-week Phase 3 VENTURE trial designed to evaluate setmelanotide in patients aged 2 to younger than 6 years with BBS or POMC, PCSK1 or LEPR deficiency. Clinically meaningful improvements were observed in both co-primary endpoints at week 52. Results of the trial demonstrated:</p>
<ul>
<li>10 of 12 patients (83%)1 achieved ≥0.2-point reduction in body mass index (BMI) Z-score;</li>
<li>-18% in mean percent change in BMI from baseline;</li>
<li>91% of caregivers reported patients had reduced hunger compared with baseline, and the caregivers also reported feelings of reduced personal burden; and</li>
<li>No new safety signals were observed.</li>
</ul>
<p>Consistent with prior experience, setmelanotide was observed to have been generally well tolerated.&nbsp;No serious adverse events (AEs) leading to study discontinuation or death were reported. The most common treatment-emergent AEs were skin hyperpigmentation (75%), vomiting (58%), nasopharyngitis (42%), upper respiratory tract infection (33%), and injection site bruising (33%).</p>


Reported Earlier, Rhythm Pharmaceuticals Publishes Phase 3 Results For Setmelanotide In Patients Between 2 And 5 Years Old

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $64 to $69.</p>


HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $69

WIIM

Rhythm Pharmaceuticals shares are trading higher after multiple firms maintained a Buy rating on the stock and raised their respective price targets.

<p>Canaccord Genuity  analyst Whitney Ijem   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $77 to $80.</p>


Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $80

<p>TD Cowen  analyst Phil Nadeau   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $55 to $65.</p>


TD Cowen Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $65

<p>Needham  analyst Joseph Stringer   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $55 to $64.</p>


Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $64

<p>Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 3.95 percent increase over losses of $(0.76) per share from the same period last year.  The company reported quarterly sales of $33.251 million which beat the analyst consensus estimate of $32.517 million by 2.26 percent.  This is a 47.76 percent increase over sales of $22.504 million the same period last year.</p>


Earnings

Earnings Beats

Rhythm Pharmaceuticals Q3 2024 GAAP EPS $(0.73) Beats $(0.82) Estimate, Sales $33.251M Beat $32.517M Estimate

<p>Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) will release its quarterly earnings report on Tuesday, 2024-11-05. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Rhythm Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $-0.81.</p>
<p>The announcement from Rhythm Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.16 in the last quarter, leading to a 1.09% drop in the share price on the following day.</p>
<p>Here's a look at Rhythm Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.71</td>
<td>-2.16</td>
<td>-0.7</td>
<td>-0.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.55</td>
<td>-2.35</td>
<td>-0.7</td>
<td>-0.76</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730746932_0_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Rhythm Pharmaceuticals were trading at $49.01 as of November 01. Over the last 52-week period, shares are up 94.77%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on Rhythm Pharmaceuticals</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Rhythm Pharmaceuticals.</p>
<p>With 8 analyst ratings, Rhythm Pharmaceuticals has a consensus rating of Buy. The average one-year price target is $61.0, indicating a potential 24.46% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Amicus Therapeutics and Apellis Pharmaceuticals, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Buy trajectory for Iovance Biotherapeutics, with an average 1-year price target of $24.5, implying a potential 50.01% downside.</li>
<li>Amicus Therapeutics is maintaining an Outperform status according to analysts, with an average 1-year price target of $17.4, indicating a potential 64.5% downside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Apellis Pharmaceuticals, with an average 1-year price target of $61.21, implying a potential 24.89% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for Iovance Biotherapeutics, Amicus Therapeutics and Apellis Pharmaceuticals are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhythm Pharmaceuticals</td>
<td>Buy</td>
<td>51.28%</td>
<td>$26.13M</td>
<td>-66.51%</td>
</tr>
<tr>
<td>Iovance Biotherapeutics</td>
<td>Buy</td>
<td>12969.75%</td>
<td>$-262K</td>
<td>-13.41%</td>
</tr>
<tr>
<td>Amicus Therapeutics</td>
<td>Outperform</td>
<td>34.04%</td>
<td>$115.41M</td>
<td>-11.93%</td>
</tr>
<tr>
<td>Apellis Pharmaceuticals</td>
<td>Neutral</td>
<td>110.26%</td>
<td>$176.59M</td>
<td>-14.18%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Rhythm Pharmaceuticals ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is also at the bottom for Return on Equity.</p>
<h3>All You Need to Know About Rhythm Pharmaceuticals</h3>
<p>Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.</p>
<h3>Key Indicators: Rhythm Pharmaceuticals's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Rhythm Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>51.28%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-115.42%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-66.51%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-10.48%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Rhythm Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>0.1</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/earnings"><strong>To track all earnings releases for Rhythm Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Rhythm Pharmaceuticals's Earnings Preview

<p>Needham  analyst Joseph Stringer   reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $55 price target.</p>


Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $55 Price Target

<p>7 analysts have expressed a variety of opinions on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $61.86, a high estimate of $70.00, and a low estimate of $52.00. This current average has increased by 7.12% from the previous average price target of $57.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729864868_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Rhythm Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Rhythm Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Rhythm Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rhythm Pharmaceuticals analyst ratings.</strong></a></p>
<h2>About Rhythm Pharmaceuticals</h2>
<p>Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.</p>
<h3>Unraveling the Financial Story of Rhythm Pharmaceuticals</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Rhythm Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>51.28%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Rhythm Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-115.42%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Rhythm Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-66.51%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-10.48%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.1</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Know

Rhythm Pharmaceuticals (RYTM) announced that the United Kingdom's Medicines & Healthcare products Regulatory Agency has expanded the marketing auth...

Rhythm Pharmaceuticals: MHRA expands marketing authorization for Imcivree

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on RYTM stock, giving a Buy rating on November 21. Ram Selvaraju has give...

Regulatory Advancements and Market Expansion Drive Buy Rating for IMCIVREE®

Rhythm Pharmaceuticals: A Key Year Ahead

Tracking Baker Brothers Portfolio - Q3 2024 Update

Oppenheimer initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating and $76 price target The firm says the company is "distin...

Rhythm Pharmaceuticals initiated with an Outperform at Oppenheimer

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Nike downgraded, FedEx upgraded: Wall Street's top analyst calls

Rhythm Pharmaceuticals (RYTM) announced that the U.S. Food and Drug Administration has approved an expanded indication for IMCIVREE to include chil...

Rhythm announces FDA approval of Imcivree for patients as young as 2

Catalyst Watch: Labor pains for Amazon & Starbucks, Nasdaq call-up for MicroStrategy and Pony AI ratings

Rhythm gets FDA approval for Imcivree for toddlers

Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report). The associated pri...

Strategic Advancements and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals

ABCL

ACAD

AFRM

ALGS

ALKS

ALMS

AMTM

AMZN

APLD

ARGNF

ARGX

AVTE

AXON

BCYC

BEIGF

BGNE

BMEA

CERS

CRVL

CVLG

DNLI

DXST

EWTX

GALT

GLATF

GLUE

GOEV

HOOK

IGMS

ILMN

IMCR

IMTX

INCY

INSM

KALA

KELYA

KNSA

KYMR

LMNR

LQDA

MDGL

MRNA

MSTR

NDSN

NMRA

NRIX

NUKK

ORCL

PLTR

PONY

QMCO

QRVO

QUBT

RARE

RDDT

REPL

RVMD

SAVA

SBUX

SGMT

SLNO

SMCI

SMMT

STOK

TCRX

TRDA

TSVT

VTVT

WBTN

WDAY

XMTR

Press Releases

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Markets

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Comments

Rhythm Pharmaceuticals

ニュース

最新ニュース Rhythm Pharmaceuticals (NASDAQ:RYTM) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル